This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SKA2 · Western blot design guide
SKA2 Western Blot Planning Guide
Plan a SKA2 Western blot around the catalog-observed 14.2 kDa band, image-backed A06326 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
SKA2 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 14.2 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 15% | |
| Positive control | Heart muscle | |
| Negative control | Bone marrow |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 14.2 kDa |
| ⓘ | Localization | Cytoplasm, cytoskeleton, spindle / Chromosome, centromere, kinetochore |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated SKA2 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Heart muscle |
| Gel % | 15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.2 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A06326 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected SKA2 Western Blot Band Size?
Use the product-observed 14.2 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 14.2 kDa | Matches the authoritative product WB observation. |
| 14.2 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected SKA2 appearancePlan around 14.2 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 14.2 kDa; use this as the primary experimental expectation. |
| Calculated mass | 14.2 kDa from UniProt Q8WVK7; retain as context. |
| Gel selection | 15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A06326. |
| Situation | Likely cause | Next action |
|---|---|---|
| 14.2 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing SKA2 band
A06326 · SKA2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for SKA2 Western blot
🧪Use Heart muscle as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Heart muscle (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for SKA2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Heart muscle | Reported tissue cells | High | Protein (HPA) | HPA → |
| Skeletal muscle | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced SKA2 Western Blot Tips
Deeper troubleshooting and optimisation questions for SKA2, answered from its protein features.
Which band should guide the blot?
Use 14.2 kDa, the observation attached to the authoritative A06326 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 14.2 kDa expectation.
Which positive control should I start with?
Start with Heart muscle, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for SKA2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A06326 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
SKA2 Western Blot Reagents
Human-reactive SKA2 Western blot reagents with authoritative product imagery.
Real WB data
Anti-SKA2 Antibody Picoband®
Cat # A06326
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q8WVK7
- Human Protein Atlas — SKA2
- A06326 product record
- PMC7858101 — Circ_0008039 supports breast cancer cell proliferation, migration, invasion, and glycolysis by regulating the miR-140-3p/SKA2 axis (Molecular oncology, 2021)
- PMC12990383 — SKA2 promotes gastric cancer progression by regulating glutathione metabolism (iScience, 2026)
- PMC2518725 — Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor (The Journal of endocrinology, 2008)
